IL17A and chronic obstructive pulmonary disease: In a study by Wang et al. (2014), in which patients with stable COPD were administered Bushen Yiqi granules or Bushen Fangchaun tablets for 180 days, serum IL-17 levels in the two HM groups were significantly lower than those in the placebo group (both, p < 0.05).